Fugazi Research warns Stablecoin Development Corporation stock uninvestable

Michael Kazley: Michael Kazley serves as CEO and Chairman of Stablecoin Development Corporation, a role he assumed in October 2025. He is also the Managing Member and General Partner of R01 Fund LP, one of the primary participants in the company's January 2026 financing round. His dual position as company executive and fund principal has been highlighted in connection with the transaction terms and ongoing asset strategy decisions. Fugazi Research: Fugazi Research is an independent publisher that produces analysis and reports on public companies, with a focus on financial structures and governance. It issued a report on Stablecoin Development Corporation that scrutinizes the entity's transformation, token concentration, and relationships among its executives, board members, and investors. The firm states that its work relies on public filings and represents subjective opinions for informational purposes. David Garcia Rios: David Garcia Rios joined the board of Stablecoin Development Corporation in September 2026 as a nominee of Sky Frontier Foundation. He holds the position of Director, Legal at the foundation, which is linked to the Sky Protocol ecosystem. His appointment followed the foundation's participation in the company's financing through stablecoin contributions. Stablecoin Development Corporation: Stablecoin Development Corporation, formerly known as NovaBay Pharmaceuticals, functions as a digital asset treasury vehicle with its balance sheet dominated by holdings in a single cryptocurrency token. The company underwent a change of control and rebranding in late 2025 and early 2026, shifting focus to staking revenue from its token position. A recent investigative report from Fugazi Research examines its governance, financing structure, and conflicts of interest tied to its major investors and leadership. Governance Overlaps: Several of the company's major investors hold board nomination rights and consent authority over its digital asset strategy, creating direct ties between funders and decision-makers. Business Model Shift: The entity transitioned from a pharmaceutical operation to a token-focused treasury structure, with revenue derived solely from staking rewards on its primary asset holding. Financing and Dilution Risks: Recent capital transactions involved exchanges of tokens and stablecoins for warrants, resulting in mechanisms that could significantly expand the share count over time through staged unlocks.